On repositioning pharma for a new era

This panel of The Pharma Summit 2011, chaired by Peter Collins, Online Business and Finance Editor at The Economist, discusses the changing demands on the industry and how they can be reconciled with pharma’s commercial interests.

The case for personalised medicine

This session of The Pharma Summit 2011, chaired by Tom Standage, Digital Editor at The Economist, explores new developments in personalised medicine and discuss whether it can be made to pay its way.

Sharing information—the payer’s perspective

In 2001 Humana, a health insurer headquartered in Kentucky with revenues of US$31bn in 2009, was looking into ways of automating its interactions with physicians’ offices. But it faced a quandary.

Going mobile at Methodist

When Methodist Hospital, a 460-bed facility serving the San Gabriel Valley near Los Angeles, wanted to create a computerised provider order entry system and digitise patient records, the IT department faced a number of challenges in coming up with a solution that would appeal to the doctors and nurses that had to use the new technology.

Virtua goes paperless

In late 2005 when Virtua, a diversified health-services company that operates four hospitals in the US state of New Jersey, decided to open a new hospital, the board decreed that it would be a paperless facility. By the time the IT department completed an assessment of what would be needed to make one facility paperless, the board decided that if the organisation was going to invest the money and human resources to do it in one facility, it may as well roll out the same technology in all its locations.

Does it work? Does that matter?

Perhaps the most visible element of mHealth is the profusion of phone apps, especially ones related to fitness and wellness. Tens of thousands are already available, and different market research firms have issued predictions for global downloads in 2012 that vary widely from just over 40 million to nearly 250 million.

Drug approvals that get the balance right

The regulation of pharmaceuticals in the US appears to have rotated from tardiness to speed. Yet both have the potential to harm or even kill patients who may already be seriously unwell.

Mental health is everyone’s business

The huge cost of mental health problems to employers has become more widely recognised. It is important that employees have ownership and take leadership of the mental health agenda, including openly sharing their experiences of mental health problems, argues Sue Baker, Director of Time to Change, England’s largest ever programme to end mental health stigma and discrimination.

Don't underestimate the socio-economic impact of depression

The economic and social effects of high levels of global depression are wide-ranging. In its most serious form, depression leads to a dramatic forestalling of human potential. Moreover, depression has a major impact on people during their most productive years. However, fewer than half of those affected globally are receiving treatment. A stronger focus on prevention, education and improved funding are vital

Global crisis of depression: reality or hype?

It is important to talk about the problem of depression. However, it is neither really a disease nor an epidemic, and over-diagnosis and over-medication are serious issues, argues Christopher Dowrick, a professor of primary medical care in Liverpool, UK.

Enjoy in-depth insights and expert analysis - subscribe to our Perspectives newsletter, delivered every week